Read/Search this Article
Abstract
We developed new intravenous sedative-hypnotic compounds with the isoindolin-1-one skeleton focusing on the water-soluble property and in vivo safety. We synthesized approximately 170 derivatives and evaluated their hypnotic effects by intravenous administration of the compounds to mice. A series of the 2-phenyl-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]isoindolin-1-one analogs, 3(-), 5(-), 27(-), and 47(-) [JM-1232(-)], showed potent sedative-hypnotic activity with good water solubility and a wide safety margin. The hypnotic doses (HD_<50>s) of these 4 compounds when administered to mice were 2.35, 1.90, 2.17, and 3.12 mg/kg, respectively, and the lethal doses (LD_<50>s) were 88.67, 64.69, >120, and >120 mg/kg, respectively. The therapeutic indexes (LD_<50>/HD_<50>) were 37.73, 34.05, >55.30, and >38.46, respectively. Among these compound, 47(-) [JM-1232(-)] is being considered as the most potential candidate for clinical trials in humans.
Journal
- Chemical & pharmaceutical bulletin [List of Volumes]
-
Chemical & pharmaceutical bulletin 55(12), 1682-1688, 2007-12-01 [Table of Contents]
The Pharmaceutical Society of Japan